Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China
· Delayed Price · Currency is CNY 3.250
+0.030 (0.93%)
Apr 29, 2026, 3:04 PM CST
SHE:002589 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 7,247 | 7,296 | 7,904 | 7,976 | 12,264 | 20,913 | Upgrade
|
| Other Revenue | - | - | 62.07 | 57.97 | 47.5 | 146.6 | Upgrade
|
| Revenue | 7,247 | 7,296 | 7,966 | 8,034 | 12,311 | 21,060 | Upgrade
|
| Revenue Growth (YoY) | -5.94% | -8.42% | -0.85% | -34.74% | -41.54% | -22.67% | Upgrade
|
| Cost of Revenue | 6,496 | 6,520 | 7,096 | 7,212 | 10,683 | 17,315 | Upgrade
|
| Gross Profit | 751.04 | 776.06 | 870.74 | 822.06 | 1,628 | 3,745 | Upgrade
|
| Selling, General & Admin | 613.29 | 659.61 | 749.93 | 835.99 | 1,503 | 2,668 | Upgrade
|
| Research & Development | 18.69 | 20.91 | 10.03 | 14.62 | 22.68 | 11.56 | Upgrade
|
| Other Operating Expenses | 26.68 | 27.37 | 36.91 | 45.72 | 52.13 | 93.7 | Upgrade
|
| Operating Expenses | 658.66 | 707.89 | 839.98 | 906.33 | 1,737 | 2,932 | Upgrade
|
| Operating Income | 92.38 | 68.16 | 30.76 | -84.27 | -108.72 | 813.41 | Upgrade
|
| Interest Expense | - | - | -193.87 | -303.7 | -407.71 | -554.42 | Upgrade
|
| Interest & Investment Income | 80.87 | 84.81 | 184.11 | 599.53 | 83.97 | 251.17 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0.02 | 0 | -0 | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -182.69 | -157 | -47.31 | -77.37 | -169.88 | -121.5 | Upgrade
|
| EBT Excluding Unusual Items | -9.44 | -4.03 | -26.33 | 134.19 | -602.33 | 388.68 | Upgrade
|
| Impairment of Goodwill | - | - | - | -0.02 | -22.94 | -39.67 | Upgrade
|
| Gain (Loss) on Sale of Investments | 5.79 | 4.9 | 30.65 | -261.66 | -1,087 | 82.15 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2 | 1.82 | 18.94 | -7.92 | -1 | 3.06 | Upgrade
|
| Asset Writedown | - | - | -0.61 | -4.89 | -24.89 | -0.24 | Upgrade
|
| Other Unusual Items | - | - | 18.93 | 4.89 | -4.98 | 31.04 | Upgrade
|
| Pretax Income | -1.65 | 2.69 | 41.57 | -135.42 | -1,744 | 465.02 | Upgrade
|
| Income Tax Expense | -44.47 | -41.21 | 0.55 | -167.39 | -4.88 | 83.01 | Upgrade
|
| Earnings From Continuing Operations | 42.83 | 43.9 | 41.02 | 31.97 | -1,739 | 382.01 | Upgrade
|
| Minority Interest in Earnings | -28.47 | -27.83 | -20.4 | -11.65 | -92.17 | -250.83 | Upgrade
|
| Net Income | 14.35 | 16.07 | 20.62 | 20.32 | -1,831 | 131.18 | Upgrade
|
| Net Income to Common | 14.35 | 16.07 | 20.62 | 20.32 | -1,831 | 131.18 | Upgrade
|
| Net Income Growth | 55.80% | -22.07% | 1.50% | - | - | -49.80% | Upgrade
|
| Shares Outstanding (Basic) | 1,605 | 1,607 | 1,505 | 1,505 | 1,477 | 1,458 | Upgrade
|
| Shares Outstanding (Diluted) | 1,605 | 1,607 | 1,505 | 1,505 | 1,477 | 1,458 | Upgrade
|
| Shares Change (YoY) | 30.32% | 6.77% | 0.01% | 1.93% | 1.30% | 0.40% | Upgrade
|
| EPS (Basic) | 0.01 | 0.01 | 0.01 | 0.01 | -1.24 | 0.09 | Upgrade
|
| EPS (Diluted) | 0.01 | 0.01 | 0.01 | 0.01 | -1.24 | 0.09 | Upgrade
|
| EPS Growth | 19.55% | -27.01% | 1.48% | - | - | -50.00% | Upgrade
|
| Free Cash Flow | -40.57 | -13.06 | 48.92 | -215.92 | 352.11 | -18.13 | Upgrade
|
| Free Cash Flow Per Share | -0.03 | -0.01 | 0.03 | -0.14 | 0.24 | -0.01 | Upgrade
|
| Dividend Per Share | - | - | 0.011 | 0.013 | - | 0.009 | Upgrade
|
| Dividend Growth | - | - | -15.38% | - | - | -50.00% | Upgrade
|
| Gross Margin | 10.36% | 10.64% | 10.93% | 10.23% | 13.23% | 17.78% | Upgrade
|
| Operating Margin | 1.27% | 0.93% | 0.39% | -1.05% | -0.88% | 3.86% | Upgrade
|
| Profit Margin | 0.20% | 0.22% | 0.26% | 0.25% | -14.87% | 0.62% | Upgrade
|
| Free Cash Flow Margin | -0.56% | -0.18% | 0.61% | -2.69% | 2.86% | -0.09% | Upgrade
|
| EBITDA | 272.96 | 244.94 | 192.34 | 130.9 | 165.95 | 1,113 | Upgrade
|
| EBITDA Margin | 3.77% | 3.36% | 2.41% | 1.63% | 1.35% | 5.29% | Upgrade
|
| D&A For EBITDA | 180.58 | 176.78 | 161.59 | 215.17 | 274.67 | 299.78 | Upgrade
|
| EBIT | 92.38 | 68.16 | 30.76 | -84.27 | -108.72 | 813.41 | Upgrade
|
| EBIT Margin | 1.27% | 0.93% | 0.39% | -1.05% | -0.88% | 3.86% | Upgrade
|
| Effective Tax Rate | - | - | 1.33% | - | - | 17.85% | Upgrade
|
| Revenue as Reported | - | - | 7,966 | 8,034 | 12,311 | 21,060 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.